Aprinoia Therapeutics said today that it has raised $11.1 million in a Series B round, led by KTB Network and DCI Partners.
The Taiwan-based biotech plans to use its new funds to advance the preclinical and clinical development of its tau PET imaging tracer and therapy programs for people with Alzheimer’s disease.
In connection with the Series B round, Kevin Kuk Hyun Kyung from KTB Network has joined Aprinoia’s board of directors.
“Our tracers will provide precise diagnosis of tau pathologies for patients and potentially for people without obvious clinical symptoms. More importantly, the tracers will be crucial for developing therapeutics and helping doctors precisely prescribe treatments and track treatment efficacies in patients,” founder & CEO Ming-Kuei Jang said in prepared remarks.
“We are also very excited about the progress we have made with our therapeutic platforms. We are building collections of small molecules and antibodies with diverse properties and therapeutic potentials. We are fortunate to have dedicated teams, collaborators, and investors working together to find comprehensive solutions for our research and medical communities, and ultimately for our patients.”
“We are thrilled to invest in Aprinoia alongside with top-tier investors in the life science industry. Moreover, we are delighted to partner with world-class talents at Aprinoia,“ Kyung added.
Aprinoia’s pipeline includes three diagnostic and two therapeutic product candidates. Its most advanced tau PET imaging tracer has made it to human clinical trials in the U.S. and Japan.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.